This is the authors' abstract. We don't add key points for this paper.
The pharmaceutical industries face a series of challenges in the delivery of many newly developed drug molecules because of their low solubility, bioavailability, stability and polymorphic conversion.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Adawiyah et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: